Why Moderna stock just collapsed 21% | 13.01.25

Moderna (NASDAQ: MRNA) sales are slowing and Moderna shares are falling – a lot. Shares of the coronavirus vaccine maker plunged 21.2% through 10:20 a.m. ET Monday after updating investors on its 2024 performance and issuing new forecasts for 2025. Moderna estimates it ended 2024 with sales of products between $3 billion and $3.1 billion, as it shifted its focus to treating COVID-19 as an “endemic” disease rather than a new pandemic that is spreading propagates. CEO Stéphane Bancel said Moderna had reduced its “operating costs by more than 25% compared to 2023” and planned to make further cost reductions of $1 billion in 2025 and $500 million additional in 2026, which should increase profits.Continue readingMore articles on MotleyFool More articles on MotleyFool